Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Is any audio available from that presentation yesterday ?
It was a scam promoted by undisclosed stock promoters then, and it doesn’t look like much has changed since then.
Adam Feuerstein had their number years ago: https://www.thestreet.com/investing/stocks/biotech-stock-mailbag-aspenbio-10741455
I've been in this dog since it was Pro-Pharma. Lost tons. Any good reason to stay??? Anyone???
December presentation
https://investor.galectintherapeutics.com/static-files/e02430e7-e6f8-4b46-b174-461df8d85a84
Last 10-Q
https://www.sec.gov/ix?doc=/Archives/edgar/data/1133416/000119312520288500/d204131d10q.htm
They could be close to partnership. More data soon as well imo.
Started accumulating.
I saw on Stock Twits a link to an article that referenced that GALT’s Belapectin *IS* being studied in an animal pre-clinical trial.
HNY BooDog and glty
Took a starter 2.25. Happy new year!!
They seem to be averse to giving shareholders anything to hope for in the next 12 months. Everything is downplayed; almost got the impression that NASH-RX was being done as a lark. Of course I knew that wasn’t true, but after that CC many months ago ... well, it was depressing. That ceo is gone.
I seriously don’t think they are pursuing Covid at all.
Yep, such is life in bio plays unfortunately
That was a missed opportunity and very disappointing. I thought this new guy was going to be more cognizant of PR and shareholder communications.
Buckysherm said,
They talked about Covid affecting the NASH trial, but nothing about research for GRMD02 treating Covid.
They talked about Covid affecting the NASH trial, but nothing about research for GRMD02 treating Covid.
I was wrong. The entire call was NASH-Rx and restating company history.
Well someone's sure been dumping this into the close. We'll see what the CEO has to say in about 2 minutes lol.
Todays premarket action was clearly a strong indication that GALT's new CEO has some real & relevant material progress to announce soon right bucky, imho anyways tick tick tick tick tick...
I inserted a goofy face to indicate that I was just kidding on the last sentence, but it came out as question marks.
I am expecting almost all of the call to be on the NASH 2b/3 trial. I had hoped for some Covid news some time ago, but have given up on that. Covid would have taken away from Shlevin’s golf game, but now that he’s not CEO, that might be a possibility. ??
Agreed buddy! Stars certainly appear to be aligning, and it's a great time for the new CEO to be brought in here!
If they dont talk about COVID we need to all complain. I think they will though. The argument is laid out so well.
Agreed Chess Master! I'm definitely looking forward to tuning into the Conference Call at 4pm market close woot-woot!
Did you read this article? This makes an amazing case for use as a COVID-19 treatment.
Here's the information on todays market close Conference Call folks>>>
Galectin Therapeutics Announces Investor Conference Call and Webinar on September 29, 2020
September 22 2020 - 08:04AM
GlobeNewswire Inc.
Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, announced today that the Company will host an investor conference call and webinar to discuss the Company’s NASH-RX clinical trial and to introduce its new CEO, Joel Lewis. The Investor Call is scheduled for Tuesday, September 29, 2020, at 4:00 p.m. EDT.
The presentation can be accessed by dialing (844) 899-6544 and entering the conference ID: 3695038 or at the following webcast link: https://edge.media-server.com/mmc/p/hmudntyg. A copy of the presentation to be used for the call can be found on the Company’s website at https://investor.galectintherapeutics.com/investor-relations.
The call is expected to last one hour, including a Q&A session that will follow the formal remarks. The Company encourages the investment community to submit their questions in advance to: info@galectintherapeutics.com and no later than Friday, September 25th at 4 PM EDT.
Let's see what the new CEO has to say as they definitely appear to have secured the necessary/required funding to conduct real deal trials now right bucky!
So todays 4pm market close GALT CC should be very revealing imho glty!
Galectin Therapeutics (GALT) is Due for a COVID-19 Makeover
GALT up 36% on COVID-19 speculation
https://emerginggrowth.com/galectin-therapeutics-galt-is-due-for-a-covid-19-makeover/
The former CEO Shlevin announced the 2b/3 trial months ago, and I got the impression that it was done as a lark and the company didn’t expect the trial to do well. Of course I knew that ain’t true, but that’s the tenor / timbre (?) he conveyed at the time.
Wakey wakey eggs & bakey;)
Galectin commences its adaptive phase 3 trial.
Looking forward to the CC at market close today and hearing what the new CEO has to say about the pending clinical trials glty
After about 3 years of “gloom, despair and agony on me” an up day like this is a delight.
You have to subscribe to see the article. I thought that after a few weeks such articles could be viewed by everyone. What’s the deal?
Copied from another board :
“Furthermore, we detected about ~3.4x upregulation of LGALS3BP, which is known to induce the expression of IL-6 by stromal cells in Galectin-3-dependent manner (Silverman et al., 2012). Of note, Galectin-3 has long been considered an attractive drug target in combating various forms of TGF-ß-mediated fibrosis and pathological inflammatory conditions (Brinchmann et al., 2018; Mackinnon et al., 2012; Shen et al.,2018; Yu Lili et al., 2013). Inhibition of Galectin-3-mediated signalling pathways hence represents another potential therapeutic target against COVID-19.”
https://www.medrxiv.org/content/10.1101/2020.04.27.20081810v1
Did you post the correct link? If you did, at what point in the video is Galactin discussed?
Great video about Galectins and the role in COVID-19
About time for another GALT chart, right Clay ?
The company doesn’t talk because there has been NOTHING to talk about for 2 years ! Other than the rights offering and a couple of patents.
GALT has initiated the adaptive Ph2b/Ph3 with a very favorable primary end point (progression to Varices)-it is now posted on the FDA Clinical Trials site:
https://clinicaltrials.gov/ct2/show/NCT04365868
This end point is a duplicate of the positive results in the original Ph2 CX trial and points to a strong likelihood of a success in the Ph3
I'm surprised that GALT hasn't done a Press Release yet about this but it's possible there is additional news that will be included with this.
Stock is up 13% today and this is the likely reason for that increase.
So minus cash the “value” of the company is only $50 Mill. Wow.
Very few posts. Pretty sad the company doesnt talk. There is nothing to talk about $50 mil in cash just sitting there.
Any update on ph where you been
Can you pm what you think phil expect pps will be, in send over your phone number
Bucky, I hope you didn’t completely abandon CYDY. Otherwise, I fear you have backed the wrong horse.
Once the correct number of patients reach 1 year or so, there will not be much down time while results are compiled. But FDA will require much too long to “think about it”. This was expected to take 3 years anyway. 1 or 2 qtrs of trial length added unfortunately.
So here is combo of bad news
1. The feedback was received in late October - this means FSA met their deadline of 75 days to give comments. Co decided to hold that news till Good news related to Siemens came out and they had to give it in 10-q
2. Surrogate end point changed - this means they have to add some specific end point - this may add to duration of trial
“. In its comments, the FDA seemingly is departing from its earlier implied potential support of the use of progression to varices as a surrogate endpoint for accelerated approval. “
3. The protocol is being redesigned with help of experts - this means resubmission of new protocol - the 75 day clock starts again
4. I mis-read about new trial but the effect is the same. The new design will be conducted as 2 part trial
Part A - Adaptive portion with interim futility analysis allowing early termination of trial in case of not good interim results
Part B - this is being now called as real phase 3 study and will have parameters adapted based on results of part A. It will have more criteria, more inclusion, 2 year dosing for at least 500 patients.
If the part B or P3 shows good results, it could go for approval or need another P3 study.
4. Co expects to dose 1st patient in Q1-2020 but we do not know what is the patient numbers and duration required for part A of study meaning it is really 2 studies.
All this mess- co is screwed up now. Assuming Q1-2020 start, the interim analysis will be for at least 1/3rd patients (170-200) to complete at least 24-36 weeks of treatment - so we are looking at 18 months for interim futility analysis. Then if positive results continue all patient enrollment and 104 week treatment - total time 3+ years.
This is a very very long path - unless someone buys this company, not a good candidate for investment till interim analysis.
Welcome year end tax losses.
REALIZE FDA DELAY = VERY POSITIVE - We dont know what they filed with the FDA because they never told us being the wonderful communicators that they are. what we do know is that whatever it was it was probably bad. The track record GALT has on clinical trial design is horrendous. RESULTS are Phenomenal but the DESIGNS always suck. They were going to probably have a 2 year study with a read out in year 3. Now shareholders have a chance. they could stop the trial on some people early once they show efficacy.
Shlevin messed the timing and trial up dont give him or the other directors a chance - do not vote for them.
Followers
|
79
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
3839
|
Created
|
03/21/07
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |